Calpain-induced Proteolysis After Transient Global Cerebral Ischemia and Ischemic Tolerance in a Rat Model

The activation of the [Ca²⁺]-dependent cysteine protease calpain plays an important role in ischemic injury. Here, the levels of two calpain-specific substrates, p35 protein and eukaryotic initiation factor 4G (eIF4G), as well as its physiological regulator calpastatin, were investigated in a rat model of transient global cerebral ischemia with or without ischemic tolerance (IT). Extracts of the cerebral cortex, whole hippocampus and hippocampal subregions after 30 min of ischemia and different reperfusion times (30 min and 4 h) were used. In rats without IT, the p35 levels slightly decreased after ischemia or reperfusion, whereas the levels of p25 (the truncated form of p35) were much higher than those in sham control rats after ischemia and remained elevated during reperfusion. The eIF4G levels deeply diminished after reperfusion and the decrease was significantly greater in CA1 and the rest of the hippocampus than in the cortex. By contrast, the calpastatin levels did not significantly decrease during ischemia or early reperfusion, but were upregulated after 4 h of reperfusion in the cortex. Although IT did not promote significant changes in p35 and p25 levels, it induced a slight increase in calpastatin and eIF4G levels in the hippocampal subregions after 4 h of reperfusion.     

Cerebral malaria: role of microparticles and platelets in alterations of the blood-brain barrier

Brain lesions of cerebral malaria (CM) are characterised by a sequestration of Plasmodium falciparum-parasitised red blood cells (PRBC), leucocytes and platelets within brain microvessels, by an excessive release of pro-inflammatory cytokines as well as by disruption of the blood-brain barrier (BBB). We evaluated the possibility that PRBC and platelets interact and induce functional alterations in brain endothelium. Using an in vitro model of endothelial lesion, we showed that platelets can act as bridges between PRBC and endothelial cells (EC) allowing the binding of PRBC to endothelium devoid of cytoadherence receptors. Furthermore, platelets potentiated the cytotoxicity of PRBC for brain EC by inducing an alteration of the integrity of their monolayer and increasing their apoptosis. These findings provide insights into the mechanisms by which platelets can be deleterious to the brain endothelium during CM. Another aspect of inflammatory and infectious diseases is that they often lead to activation of vascular and blood cells. Such activation results in an enhanced vesiculation, i.e. the release of circulating microparticles (MP). We thus explored plasma levels of endothelial MP in Malawian children with malaria. Plasma MP numbers were markedly increased on admission only in patients with severe malaria complicated with coma. Using the experimental mouse model of CM, we evaluated the pathogenic implications of MP using genetically deficient mice in which the capacity to vesiculate is impaired. Such mice, lacking the ABCA-1 gene, upon infection by Plasmodium berghei ANKA, showed complete resistance to CM. When purified from infected susceptible animals, MP were able to reduce normal plasma clotting time and to significantly enhance tumour necrosis factor release from na?ve macrophages. Altogether these data provide a novel insight into the pathogenic mechanisms leading to the neurological syndrome. The finding that ABCA-1 gene deletion confers complete protection against cerebral pathology, linked to an impaired MP production, provides new potential targets for therapeutic amelioration of severe malaria.     

Structural basis for small G protein effector interaction of Ras-related protein 1 (Rap1) and adaptor protein Krev interaction trapped 1 (KRIT1)

Cerebral cavernous malformations (CCMs) affect 0.1–0.5% of the population resulting in leaky vasculature and severe neurological defects. KRIT1 (Krev interaction trapped-1) mutations associate with ∼40% of familial CCMs. KRIT1 is an effector of Ras-related protein 1 (Rap1) GTPase. Rap1 relocalizes KRIT1 from microtubules to cell membranes to impact integrin activation, potentially important for CCM pathology. We report the 1.95 Å co-crystal structure of KRIT1 FERM domain in complex with Rap1. Rap1-KRIT1 interaction encompasses an extended surface, including Rap1 Switch I and II and KRIT1 FERM F1 and F2 lobes. Rap1 binds KRIT1-F1 lobe using a GTPase-ubiquitin-like fold interaction but binds KRIT1-F2 lobe by a novel interaction. Point mutagenesis confirms the interaction. High similarity between KRIT1-F2/F3 and talin is revealed. Additionally, the mechanism for FERM domains acting as GTPase effectors is suggested. Finally, structure-based alignment of each lobe suggests classification of FERM domains as ERM-like and TMFK-like (talin-myosin-FAK-KRIT-like) and that FERM lobes resemble domain “modules.”     

The role of co-activation in strength and force modulation in the elbow of children with unilateral cerebral palsy

To study the role of coactivation in strength and force modulation in the elbow joint of children and adolescents with cerebral palsy (CP), we investigated the affected and contralateral arm of 21 persons (age 8-18) with spastic unilateral CP in three tasks: maximal voluntary isokinetic concentric contraction and passive isokinetic movement during elbow flexion and extension, and sub-maximal isometric force tracing during elbow flexion. Elbow flexion-extension torque and surface electromyography (EMG) of the biceps brachii (BB) and triceps brachii (TB) muscles were recorded. During the maximal contractions, the affected arm was weaker, had decreased agonist and similar antagonist EMG amplitudes, and thus increased antagonist co-activation (% of maximal activity as agonist) during both elbow flexion and extension, with higher coactivation levels of the TB than the BB. During passive elbow extension, the BB of the affected arm showed increased resistance torque and indication of reflex, and thus spastic, activity. No difference between the two arms was found in the ability to modulate force, despite increased TB coactivation in the affected arm. The results indicate that coactivation plays a minor role in muscle weakness in CP, and does not limit force modulation. Moreover, spasticity seems particularly to increase coactivation in the muscle antagonistic to the spastic one, possibly in order to increase stability.     

黄芪注射液对2型糖尿病动物模型KKAy小鼠脑微血管病变的影响

目的：观察黄芪注射液对2型糖尿病动物模型KKAy小鼠脑微血管病变的影响,探讨黄芪注射液对糖尿病脑血管病变的保护作用。方法：饲养至14周龄的雄性KKAy小鼠随机分成模型组和黄芪注射液治疗组（每日腹腔给药,剂量为3mL／kg）,同龄雄性C57BL／6J小鼠作为对照组。血糖仪测量20、24、28周龄时各组小鼠的空腹血糖水平。28周龄时处死各组小鼠,放射免疫法检测血清6-酮-前列腺素-F1α（6-Keto-PGF1α）和血栓素B2（TXB2）的含量。透射电子显微镜观察脑组织超微结构变化。结果：模型组KKAy小鼠从20周龄开始血糖水平明显高于正常组小鼠（P〈0．01）;黄芪治疗组小鼠从20周龄开始血糖水平明显高于正常组小鼠（P〈0．01）,但低于模型组小鼠（P〈0．05或P〈0．01）。模型组小鼠血清6-Keto—PGF1α水平较正常组降低（P〈0．01）,TXB2含量增高（P〈0．01）;与模型组相比,黄芪注射液治疗组小鼠6-Keto—PGF1α水平升高（P〈O．01）,TXB：含量下降（P〈0．01）。透射电镜显示模型组小鼠神经细胞胞核染色质疏松,线粒体肿胀,粗面内质网缩小,核糖体减少;治疗组小鼠以上病变明显改善。结论：黄芪注射液可以有效改善2型糖尿病动物模型KKAv小鼠脑微血管病变,保护神经细胞结构。     

兔脑微栓塞模型脑血流动力学的CT灌注动态变化

目的探讨兔脑微栓塞模型CT灌注成像（CT perfusion imaging,CTPI）脑血流动力学的动态变化规律。方法 30只新西兰兔,随机分成两组,A组：假手术对照组5只,B组：微栓塞组25只。经颈外动脉向颈内动脉注入直径约0.5 mm的SiO2颗粒10枚,分别于栓塞后30 min、3 h、6 h、12 h及24 h行CTPI,24 h处死动物取脑组织行HE染色。根据HE染色结果将模型分为缺血组和梗死组,分别观察其脑血流量（cerebral blood flow,CBF）、脑血容积（cerebral blood volume,CBV）和平均通过时间（mean transit time,MTT）的动态变化规律。结果 A组CTPI及HE染色均未见明显异常。B组3只因实验意外死亡,1只因下肢静脉穿刺失败导致CTPI失败,21只行CTPI,其中18只灌注异常,3只未见明显异常。18只灌注异常的兔中,HE染色10只脑梗死,7只脑缺血,1只未见明显异常。30 min时7只缺血兔脑不同程度低灌注,表现为CBF降低,MTT延长,CBV无显著变化,3～6 h低灌注进一步加重,CBV值略降低,12 h低灌注不同程度恢复,24 h进一步恢复。30 min时10只梗死兔脑明显低灌注,表现为CBF及CBV显著降低,MTT显著延长,3只兔低灌注分别在3 h、6 h及12 h不同程度恢复,然后下一时间又迅速降低并随着时间延长进一步加剧,其余7只兔低灌注程度随时间延长逐渐加剧或在一定水平上波动。结论脑缺血3～6 h低灌注最明显,12～24 h低灌注不同程度恢复,而脑梗死随时间延长低灌注程度不断加重或一过性恢复后再次加重。脑缺血的特征是CBF和CBV的不匹配,缺血组织CBF显著降低,CBV无显著变化,而脑梗死则表现为这两个参数的一致性下降。     

奥扎格雷钠联合依达拉奉治疗急性脑梗死的疗效观察

目的:观察奥扎格雷钠联合依达拉奉治疗急性脑梗死的临床疗效。方法:将160例急性脑梗死患者随机分为治疗组和对照组,每组各80例,治疗组采用注射用奥扎格雷钠联合依达拉奉治疗,对照组仅采用注射用奥扎格雷钠治疗,观察两组患者入院及治疗14d后临床疗效,神经功能缺损评分变化并进行对比分析。结果:治疗组的显效率为85.9%(67/78),对照组显效率为70.9%(56/79),两组显效率有显著性差异(x2=5.12,P=0.022),两组患者治疗14d后,神经功能的恢复情况与治疗前相比均有显著性差异(P<0.05),且治疗组与对照组治疗后比较有显著性差异,具有统计学意义(P<0.05)。结论:奥扎格雷钠联合依达拉奉治疗急性脑梗死较单独使用奥扎格雷钠疗效显著,是治疗急性脑梗死的有效方法。     

外科手术在高血压脑出血治疗中的应用

高血压脑出血是当今社会一种发病率及死亡率都非常高的神经科疾病,对于它的治疗,则是神经内外科的重点难点。目前治疗高血压脑出血的方法分为内科保守治疗和外科手术治疗两种,作者阅读了大量国内外临床相关文献,综述了高血压脑出血相关内外科治疗的方法,以及具体应用,望能为其相关研究提供有益的思路。     

消栓通胶囊抗脑缺血作用的实验研究

目的:观察消栓通胶囊对双侧颈总动脉结扎的大鼠脑缺血的保护作用;对小鼠断头后存活时间的影响.方法:采用结扎大鼠双侧颈总动脉以造成脑缺血模型,观察消栓通胶囊的药理作用.结果:①a.消栓通胶囊对双侧颈总动脉结扎大鼠脑含水量及脑指数有显著影响,消栓通胶囊三个剂量组(0.20 g/kg、0.40 g/kg、0.80 g/kg),脑含水量明显减少,与模型组有显著差异(P＜0.05或P＜0.01).b.组织病理学检查表明消栓通胶囊组的脑组织神经细胞浓缩及深染较脑缺血模型组明显减轻;神经胶质细胞肿胀及间质疏松程度均明显轻于模型组.②消栓通胶囊三个剂量组(0.20 g/kg、0.40 g/kg、0.80 g/kg)均能明显降低全血粘度值,与模型组比较有明显差异(P＜0.05或P＜0.01);③消栓通胶囊三个剂量组(025g/kg、0.50g/kg、1.00 g/kg)给药14d,与正常组比较可延长小鼠断头喘气的时间(P＜0.05或P＜0.01).结论:消栓通胶囊对大鼠结扎双侧颈总动脉所致脑缺血损伤具有明显的保护作用.     

急性脑梗死患者血浆同型半胱氨酸水平及其相关因素分析*

目的:探讨急性脑梗死患者血浆同型半胱氨酸水平及相关因素。方法:采用高效液相色谱法检测232例急性脑梗死患者血浆Hcy水平,并对其相关因素进行统计学分析。结果:急性脑梗死组患者血浆Hcy水平明显升高(P<0.05);并与叶酸及维生素B12水平显著相关。不同年龄段急性脑梗死患者血浆Hcy水平具有差异。并与颈动脉粥样硬化斑块相关联。结论:血浆Hcy水平增高是脑梗死的危险因素之一,并与患者年龄、血液中叶酸、维生素B12水平及脑梗死性质相关联。